Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer

Uday B. Dandamudi, Laurel M. Adams, Brendan Johnson, John Bauman, Shannon Morris, Sharon Murray, R. Timothy Webb, Elaina Gartner, Raymond Hohl, Lionel D. Lewis

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Purpose: The neurokinin-1 receptor antagonist, casopitant, is a weak-to-moderate inhibitor of cytochrome P450 isoenzyme 3A4 (CYP3A) and has the potential to inhibit the metabolism of CYP3A substrates such as docetaxel. Methods: Fourteen cancer patients were enrolled in this phase 1, open-label, randomized, two-period crossover study. Intravenous (i.v.) docetaxel was coadministered with oral ondansetron and dexamethasone with (Regimen B) or without (Regimen A) 150 mg single-dose oral casopitant. Results: The geometric least-squares mean Regimen B: Regimen A ratios (90% confidence interval) for docetaxel maximum plasma concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 0.97 (0.83, 1.12) and 1.06 (0.94, 1.19), respectively. Coadministration of casopitant and docetaxel was well tolerated, with adverse event profiles and absolute neutrophil count nadirs similar for both treatments. Conclusions: C max and AUC of docetaxel were similar when given as monotherapy or when given in combination with casopitant. Likewise, absolute neutrophil count nadirs were similar for docetaxel alone or docetaxel with casopitant.

Original languageEnglish (US)
Pages (from-to)783-790
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number4
DOIs
StatePublished - Apr 1 2011

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer'. Together they form a unique fingerprint.

Cite this